TY - JOUR
T1 - Novel α-Lipoic Acid/3- n-Butylphthalide Conjugate Enhances Protective Effects against Oxidative Stress and 6-OHDA Induced Neuronal Damage
AU - Uppakara, Kwanchanok
AU - Jamornwan, Sopana
AU - Duan, Liang Xing
AU - Yue, Kai Rui
AU - Sunrat, Chotchanit
AU - Dent, Erik W.
AU - Wan, Sheng Biao
AU - Saengsawang, Witchuda
AU - Saengsawang, Witchuda
AU - Saengsawang, Witchuda
N1 - Publisher Copyright:
© 2020 American Chemical Society.
PY - 2020/6/3
Y1 - 2020/6/3
N2 - Neurodegenerative diseases are irreversible conditions that result in progressive degeneration and death of nerve cells. Although the underlying mechanisms may vary, oxidative stress is considered to be one of the major causes of neuronal loss. Importantly, there are still no comprehensive treatments to completely cure these diseases. Therefore, protecting neurons from oxidative damage may be the most effective therapeutic strategy. Here we report a neuroprotective effects of a novel hybrid compound (dlx-23), obtained by conjugating α-lipoic acid (ALA), a natural antioxidant agent, and 3-n-butylphthalide (NBP), a clinical anti-ischemic drug. Dlx-23 protected against neuronal death induced by both H2O2 induced oxidative stress in Cath.-a-differentiated (CAD) cells and 6-OHDA, a toxin model of Parkinson's disease (PD) in SH-SY5Y cells. These activities proved to be more potent than the parent compound (ALA) alone. Dlx-23 scavenged free radicals, increased glutathione levels, and prevented mitochondria damage. In addition, live imaging of primary cortical neurons demonstrated that dlx-23 protected against neuronal growth cone damage induced by H2O2. Taken together these results suggest that dlx-23 has substantial potential to be further developed into a novel neuroprotective agent against oxidative damage and toxin induced neurodegeneration.
AB - Neurodegenerative diseases are irreversible conditions that result in progressive degeneration and death of nerve cells. Although the underlying mechanisms may vary, oxidative stress is considered to be one of the major causes of neuronal loss. Importantly, there are still no comprehensive treatments to completely cure these diseases. Therefore, protecting neurons from oxidative damage may be the most effective therapeutic strategy. Here we report a neuroprotective effects of a novel hybrid compound (dlx-23), obtained by conjugating α-lipoic acid (ALA), a natural antioxidant agent, and 3-n-butylphthalide (NBP), a clinical anti-ischemic drug. Dlx-23 protected against neuronal death induced by both H2O2 induced oxidative stress in Cath.-a-differentiated (CAD) cells and 6-OHDA, a toxin model of Parkinson's disease (PD) in SH-SY5Y cells. These activities proved to be more potent than the parent compound (ALA) alone. Dlx-23 scavenged free radicals, increased glutathione levels, and prevented mitochondria damage. In addition, live imaging of primary cortical neurons demonstrated that dlx-23 protected against neuronal growth cone damage induced by H2O2. Taken together these results suggest that dlx-23 has substantial potential to be further developed into a novel neuroprotective agent against oxidative damage and toxin induced neurodegeneration.
KW - 3- n-butylphthalide
KW - Lipoic acid
KW - Parkinson's disease
KW - hybrid
KW - neuroprotection
KW - oxidative stress
UR - http://www.scopus.com/inward/record.url?scp=85085904430&partnerID=8YFLogxK
U2 - 10.1021/acschemneuro.0c00105
DO - 10.1021/acschemneuro.0c00105
M3 - Article
C2 - 32374999
AN - SCOPUS:85085904430
SN - 1948-7193
VL - 11
SP - 1634
EP - 1642
JO - ACS Chemical Neuroscience
JF - ACS Chemical Neuroscience
IS - 11
ER -